Troubled Realm Therapeutics Selling Assets, Delisting From London AIM

US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.

AssetManagement
Clinical Failures Have Forced Realm To Seek Buyers • Source: Shutterstock

Realm Therapeutics PLC, which last November launched a strategic review, said it plans to sell assets for up to $10m to Urgo US Inc, delist from London's AIM market, while continuing to hold discussions with "interested parties" that might lead to a takeover offer. 

Updating on its efforts to seek strategic alternatives after its key asset failed in clincial trials, the Malvern, PA-based biotech...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.